New drug combo aims to outsmart pancreatic cancer before surgery
Disease control
Not yet recruiting
This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers …
Phase: PHASE1 • Sponsor: Aram Hezel • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC